Today, patients on insulin receive injections daily, or even more often, but both companies are working to change that.

Eli Lilly LLY announced positive topline results from two phase III studies, QWINT-1 and QWINT-3, which evaluated efsitora ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

Eli Lilly (LLY) stock will be in focus as two phase 3 trials for its once-weekly insulin efsitora alfa succeed against daily ...

Eli Lilly on Thursday said topline results from two late-stage studies showed that its weekly insulin injection had similar results to the widely used daily insulins. The drugmaker said topline ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in ...

In the trial, efsitora met the primary endpoint of non-inferior A1C reduction. For the efficacy estimand, efsitora reduced A1C by 1.34% compared to 1.26% for insulin degludec resulting in an A1C of ...

Eli Lilly also announced an $800 million facility expansion in Kinsale, Ireland. That site started to manufacture drugs last year to help meet demand for the company's diabetes and obesity ...

(RTTNews) - Eli Lilly and Co. (LLY ... per patient-year of exposure of 0.58 with efsitora vs. 0.45 with insulin degludec. The company noted that estimated combined rates of severe or clinically ...